Want to see TSE:DTC full AI Analyst Report?
DTC Stock Chart & Stats
C$0.38
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.38
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.37 - C$0.93
Previous CloseN/A
Volume1.02K
Average Volume (3M)68.27K
Market Cap
C$29.56M
Enterprise ValueC$31.08
Total Cash (Recent Filing)C$2.95M
Total Debt (Recent Filing)C$1.56M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Accum® Intracellular Delivery PlatformOwning the Accum® intracellular delivery platform provides a durable technological moat for biologics development. A platform that improves intracellular delivery can enable multiple programs (oncology, infectious disease), supporting diversified pipeline opportunities and long-term licensing or partnership potential.
Improved Balance Sheet Position TTMRestoring positive shareholders' equity and rising assets signal improved financial headroom versus prior years. This reduces immediate solvency risk and extends runway, allowing continued R&D investment and partner discussions without immediate operational disruption from insolvency threats.
Material Reduction In Annual Net Loss From 2024 To 2025A substantial year-over-year reduction in net loss indicates management action on cost structure and program prioritization. Sustained expense discipline can extend runway and make future financing less dilutive, improving prospects for reaching clinical milestones or partnering opportunities.
Bears Say
No Revenue; Development-stage ProfileLack of product revenue means the company must rely on R&D progress and external funding to sustain operations. Without commercial cash generation, the business remains dependent on successful clinical outcomes or partnerships to transition from pre-revenue to self-sustaining operations.
Persistent Cash Burn And Negative Operating Cash FlowConsistent negative operating and free cash flow reflects ongoing funding needs for development programs. Persistent cash burn increases the likelihood of future capital raises, which can dilute shareholders and distract management, and constrains the ability to scale or commercialize without partnerships.
Financing And Dilution Risk From Prior Negative Equity And DebtHistory of negative equity plus outstanding debt creates structural financing risk: if losses continue, the company will likely need external capital. That raises dilution risk and potential covenant or creditor pressures, which can limit strategic flexibility and slow program advancement.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.36 and its highest was C$0.93 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$29.56M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 75 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -C$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―